Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) hit a 52-week high after unveiling top-line data from the first phase III study of ITI-007, showing the drug met the primary endpoint of antipsychotic efficacy in acutely exacerbated schizophrenia, without demonstrating the side effects that usually lead to patients discontinuing treatment.